The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol

The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol

Abstract Background Window-of-opportunity trials, evaluating the engagement of drugs with their biological target in the time period between diagnosis and standard-of-care treatment, can help prioritise promising new systemic treatments for later-phase clinical trials. Renal cell carcinoma (RCC), th...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Stephan Ursprung, Helen Mossop, Ferdia A. Gallagher, Evis Sala, Richard Skells, Jamal A. N. Sipple, Thomas J. Mitchell, Anita Chhabra, Kate Fife, Athena Matakidou, Gemma Young, Amanda Walker, Martin G. Thomas, Mireia Crispin Ortuzar, Mark Sullivan, Andrew Protheroe, Grenville Oades, Balaji Venugopal, Anne Y. Warren, John Stone, Tim Eisen, James Wason, Sarah J. Welsh, Grant D. Stewart
Format: article
Langue:EN
Publié: BMC 2021
Sujets:
Clinical trial protocol [MeSH]
Clear cell renal cell carcinoma [MeSH]
Phase II clinical trial [MeSH]
Bayesian adaptive trial
Olaparib [MeSH]
Cediranib [MeSH]
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/c51c1579691f49dabf5c4459307d8325
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/c51c1579691f49dabf5c4459307d8325

Documents similaires